TESARO Inc (NASDAQ:TSRO) has been upgraded to Buy in a statement by Bank of America Corp. earlier today.
- Updated: October 10, 2016
Having a price of $99.26, TESARO Inc (NASDAQ:TSRO) traded -0.63% lower on the day. With the last stock price up 43.94% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. The company has recorded a 50-day average of $96.42 and a two hundred day average of $68.96. Volume of trade was up over the average, with 1,364,793 shares of TSRO changing hands over the typical 1,009,710
Bank of America Corp. has upgraded TESARO Inc (NASDAQ:TSRO) to Buy in a statement released on Monday October 10, 2016.
On Tuesday September 06, 2016, Lake Street released a statement for TESARO Inc (NASDAQ:TSRO) bumped up the target price from $0.00 to $114.00 that suggested an upside of 0.31%.
With a market capitalization of $0, TESARO Inc has with a one year low of $29.51 and a one year high of $110.48 .
A total of 10 analysts have released a report on TESARO Inc. Eight analysts rating the company a strong buy, four analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $89.00.
General Company Details For TESARO Inc (NASDAQ:TSRO)
TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform. It offers VARUBI (rolapitant), which is an oral substance P/neurokinin 1 (NK-1) receptor antagonist for use in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. It is developing IV formulation of rolapitant, which has completed various Phase 1 clinical trials. Its niraparib is an orally active and poly (ADP-ribose) polymerase (PARP) inhibitor. Its immuno-oncology platform has immuno-oncology programs, which include TSR-022 and TSR-042.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.